A borophosphate glass composition including B.sub.2O.sub.3, P.sub.2O.sub.5, and CaO, and optionally a source additive selected from: Li.sub.2O, Na.sub.2O, K.sub.2O, Al.sub.2O.sub.3, ZnO, MgO, Fe.sub.2O.sub.3/FeO, CuO/Cu.sub.2O, and mixtures thereof, as defined herein. Also disclosed are bioactive compositions or substrates including the disclosed borophosphate glass composition, and at least one live cell. Also disclosed are methods of inhibiting or increasing the relative amount of species containing boron, phosphorous, or both, being released into an aqueous solution from aborophosphate glass composition defined herein. Also disclosed is a method of proliferating cells on a bioactive substrate as defined herein. Also disclosed are related glass compositions that exclude one of B.sub.2O.sub.3, P.sub.2O.sub.5, and CaO.

Provided is a radioactive microsphere including glass having a structure represented by a formula Ca.sub.3Si.sub.2O.sub.7 and yttrium oxide contained in the glass. The radioactive microsphere has sphericity of from 0.71 to 1, and is radioactive after being activated by neutron irradiation. A method for preparing a radioactive microsphere and a radioactive filler composition is further provided. The present disclosure can be used to treat tumor by delivering radioactive microspheres to the target tissue, and then radioactive microspheres are activated by neutrons to generate radiation. The radioactivity of microspheres disappears over time, and the microspheres were dissolved and absorbed by the bone tissue in the end.

An aluminoborate glass composition, including B.sub.2O.sub.3, Al.sub.2O.sub.3, P.sub.2O.sub.5, Na.sub.2O, and CaO, as defined herein. Also disclosed are bioactive compositions including the disclosed aluminoborate glass composition, a suitable fluid, and at least one live cell. Also disclosed is method of limiting the amount of boron released into an aqueous solution from a disclosed aluminoborate-containing glass composition as defined herein. Also disclosed is a method of proliferating cells on a bioactive substrate as defined herein.

The present invention relates to a method for preparing a glass-ceramic composite, in which a bioactive material is uniformly coated on the surface of a ceramic molded body; a glass-ceramic composite, in which a bioactive material is uniformly coated on the surface of a ceramic molded body; a bone grafting material comprising the glass-ceramic composite; and a bone grafting kit comprising the glass-ceramic composite.

A borate bioactive glass is described, and may be used in the form of particles in an acidic mixture to form a borate bioactive glass paste. The borate bioactive glass paste may be used for the restoration of dentin and enamel on a tooth surface by the precipitation of calcium phosphate. The borate bioactive glass may also be used as a bone grafting material.

A glass-ceramic composition as defined herein. The glass-ceramic composition includes a first crystalline phase comprising lithium disilicate. The glass-ceramic composition can include up to 10 wt % CaO, up to 5 wt % Na.sub.2O, up to 10 wt % B.sub.2O.sub.3, and greater than 0.5 wt % ZrO.sub.2. The glass-ceramic composition can also include from 50 to 75 wt % SiO.sub.2, from 1 to 5 wt % Al.sub.2O.sub.3, from 1 to 8 wt % P.sub.2O.sub.5, and from 5 to 20 wt % Li.sub.2O. In aspects, the glass-ceramic composition can include a second crystalline phase including wollastonite, apatite, cristobalite, -quartz, lithiophosphate, or a combination thereof. Also disclosed are methods of making and using the disclosed compositions.

A bioactive glass composition for use in treating bone cancer includes 0.5-10 mol % gallium oxide or 1.0-20 mol % gallium nitrate/halide; 25 to 75 mol % silicon dioxide; 10 to 30 mol % calcium oxide and/or strontium oxide; up to 30 mol % sodium oxide; and up to 15 mol % phosphorous pentoxide. It may further comprise magnesium and/or potassium oxide. The bioactive glass composition may be positioned within a patient's bone post-surgery to promote apatite formation and to release gallium ions having a toxic effect on any remaining cancerous cells.

A method of forming a dissolvable part of amorphous borate includes: preparing a mixture comprising one or more boron compounds and one or more alkali compounds, at least one of the one or more boron compounds and the one or more alkali compounds being hydrous; heating the mixture to a melting temperature for a predetermined time to melt the mixture and release water from the mixture to form an anhydrous boron compound that is moldable, wherein the amount of alkali compound being selected to achieve an alkali oxide content of between about 10 to 25%; with the anhydrous boron compound at a molding temperature, molding the anhydrous boron compound in a mold; and cooling the anhydrous boron compound to form a solid.

A method of manufacturing a resorbable, macroporous bioactive glass scaffold comprising approximately 15-45% CaO, 30-70% SiO.sub.2, 0-25% Na.sub.2O, 0-17% P.sub.2O.sub.5, 0-10% MgO and 0-5% CaF.sub.2 by mass percent, produced by mixing with pore forming agents and specified heat treatments.

Borate-glass biomaterials comprising: aNa.sub.2O. bCaO. cP.sub.2O.sub.5. dB.sub.2O.sub.3 wherein a is from about 1-40 wt %, b is from about 10-40 wt %, c is from about 1-40 wt %, and d is from about 35-80 wt %; and wherein the biomaterial has a surface area per mass of more than about 5 m.sup.2/g. Methods of making and uses of these biomaterials.